oct_trials_OBGYN.html

OVPR SiteMap | Temple Home | Graduate Programs | Graduate Schools at Temple

Close Window

Active Clinical Trials

OB GYN

General Obstetrics Clinical Trials

Department: OB GYN	Condition (as stated in the title): Hypoactive Sexual Desire Disorder	PI Name: Ashwin Chatwani, M.D.	IRB #: 11226
A Randomized, Double-Blind, Placebo Controlled, Multicenter, 52 Week study to Evaluate the Endometrial Safety of Transdermal Testoterone (300 mcg/day) in Naturally Postmenopausal Women with Hypoactive Sexual Desire Disorder
IRB Approval Valid Through: 26-Sep-2008

Department:
OB GYN

Condition (as stated in the title):

Yeast Infections -Diagnostic Testing

PI Name:
Ashwin Chatwani, M.D.

IRB #

10934

Rapid Vaginal Yeast Infection Test Study

IRB Approval Valid Through: 5-Feb-2008

Gyncologic Oncology Trials

Department:
OB GYN

Condition (as stated in the title):

Chemotherapy Induced Nausea and Vomiting (Cancer)

PI Name:
Enrique Hernandez, M.D.

IRB #

11216

A Pivotal Phase III Observer-Blind, Randomized Clinical Trial of the Efficacy and Safety of APF 530 Compared to Aloxi for the Prevention of Acute-onset and delayed onset Chemotherapy Induced Nausea and Vomiting Following the Administration of Either Moderately or Highly Emetogenic Chemotherapy Regimen.

IRB Approval Valid Through: 3-Oct-2008

Department:
OB GYN

Condition (as stated in the title):

Advanced Squamous Cell Carcinoma of the Vulva (Cancer)

PI Name:
Enrique Hernandez, M.D.

IRB #

10074

A Phase II Trial of Radiation Therapy and Weekly Cisplatin Chemotherpy for the Treatment of Locally Advanced Squamous Cell Carcinoma of the Vulva

IRB Approval Valid Through: 25-Sept-2007

Department:
OB GYN

Condition (as stated in the title):

Carcinosarcoma of the Uterus (Cancer)

PI Name:
Enrique Hernandez, M.D.

IRB #

10075

A Phase II Evaluation of Gemcitabine (nsc #613327) and Docetaxel (nsc#628503) In the Treatment of Recurrent Or Pesistent Carcinosarcoma of the Uterus

IRB Approval Valid Through: 28-Aug-2007

Department:
OB GYN

Condition (as stated in the title):

Ovarian, Fallopian Tube or Primary Peritoneal Cancer

PI Name:
Enrique Hernandez, M.D.

IRB #

10238

A Randomized Phase II Evaluation of Topotecan (ncs #609699) Administered Daily X5 Every 3 Weeks Vs. Weekly Topotecan In the Treatment of Recurrent Platinum-sensitive Ovarian, Fallopian Tube or Primary Peritoneal Cancer

IRB Approval Valid Through: 16-Jan-2007

Department:
OB GYN

Condition (as stated in the title):

Ovarian Stromal Tumors (Cancer)

PI Name:
Enrique Hernandez, M.D.

IRB #

3937

Phase II Study of Paclitaxel For Ovarian Stromal Tumors as First Line or Second Line Therapy

IRB Approval Valid Through: 14-Jan-2008